CNBC's Jim Cramer on Monday told investors to be wary of some food and beverage stocks as investors are captivated by companies that make newly popular GLP-1s, weight loss and diabetes drugs such as Mounjaro and Zepbound.
"Stay away from these food and beverage stocks because there will be a day, that day will come, when one of them finally admits they've been hurt by the GLP-1s, and that will take down every stock in the group," he said.
But there are other variables that could contribute to weaker sales for food and beverage companies, he said. Many in the industry deny that GLP-1s are hurting sales and changing consumer behavior.
PepsiCo admitted its snack business is suffering, but attributed those declines to a consumer that has less disposable income. Cramer added that liquor companies are also seeing declines, but said this could also be due to inflated prices or perhaps to consumers choosing to use more cannabis products.
Cramer conceded that it's hard to predict just how much these drugs will affect food stocks going forward, but said they will definitely change the market.
"In the end, we just don't know what's the impact of the GLP-1s versus everything else," he said. "However, you're fooling yourself if you think these drugs didn't play some sort of role."
Sign up now for the CNBC Investing Club to follow Jim Cramer's every move in the market.
Questions for Cramer?
Call Cramer: 1-800-743-CNBC
Want to take a deep dive into Cramer's world? Hit him up!
Mad Money Twitter - Jim Cramer Twitter - Facebook - Instagram
Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com